Please ensure Javascript is enabled for purposes of website accessibility

3 Things to Watch When CVS Health Reports Earnings

By Brian Feroldi - May 2, 2016 at 1:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmacy retail giant is prepping to report its first-quarter earnings results on May 3rd. Here's a list of three areas investors should pay attention to.


CVS Health (NYSE: CVS) is set to release its first-quarter financial results this Tuesday morning before trading begins. Investors' expectations are running high: The company just capped off a transformative year, and fourth-quarter results were quite impressive. The company grew its revenue grew by 11%, and adjusted earnings per shared grew more than 26%, causing management to issue upbeat guidance for the rest of 2016.

So what should investors expect from the retail pharmacy giant this quarter? Here are three key areas that I'll be paying attention to when results hit the wire.

Quick stats on CVS Health

Market Cap

$112 billion

Trailing P/E Ratio


Forward P/E Ratio


Dividend Yield



1. The headline numbers
CVS' management is guiding for net revenue growth of 17% to 18.5%. The monster jump is mostly owed to last year's acquisitions of Target's pharmacy and clinical business and Omnicare, but the company also believes that it will show modest organic growth too.

However, management does not believe that its profits will keep pace with its strong revenue growth. Expectations are for adjusted earnings per share to land between $1.14 to $1.17. That's basically flat with the $1.14 that it recorded in the first quarter of 2015, largely due to shifting margins.

Thankfully, management is still projecting double-digit adjusted earnings per share for 2016. 

2. Are they gaining market share?
CVS Health expects that more and more employers, governments, unions, and other institutions will turn to CVS' Pharmacy Benefits Management business to help them control their spending on pharmaceuticals. 

Last quarter, the company's adjusted claims grew by a strong 6.4%, and since CVS Health welcomed 9 million new PBM members in January alone, the company looks poised to once again post market share gains.

CVS Health's retail pharmacy business is also positioned for a quarter of strong growth. The company is still in the middle of converting Target's pharmacy and clinical stores to its CVS/Pharmacy name. Management had previously communicated that the conversion process should wrap up by the end of summer.

As those stores are re-branded, CVS announced its intentions to start marketing to Target's customers, which should help them to boost their already-massive market share. Last quarter, CVS grew its market share by 65 basis points to 21.8% -- and that was accomplished with only with a handful of Target's stores being converted.


3. Looking out for shareholders?
Just like almost every other stock in the S&P 500, the market's volatility early in the year caused CVS Health's stock to decline sharply. Since management had announced their intention to repurchase about $4 billion worth of company's stock in 2016, the first quarter afford them a great opportunity to do so at favorable prices. After all, last year the company spent a total of $5 billion buying back its stock for an average price $101.23. So, with shares at one point dipping down to below $90, one would think that this quarter was a good time for the company to get aggressive.

Investors should have answers to all of these questions after results are released on May 3rd!

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CVS Health Corporation Stock Quote
CVS Health Corporation
$95.57 (0.67%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.